Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,063.06
(
-0.65%
)
US TECH 100
25,742.80
(
-0.50%
)
Dow Jones
49,141.19
(
-0.62%
)
Brent Oil
96.23
(
6.12%
)
Bitcoin
75,130.89
(
-1.00%
)
News Focus
News Focus
Post# of 58
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

whytestocks

Send PM Follow Ignore
Followers 131
Posts 15004
Boards Moderated 0
Alias Born 06/04/2018

whytestocks

Re: None

Sunday, 10/27/2019 1:00:23 PM

Sunday, October 27, 2019 1:00:23 PM

Post# of 58
News: $AGIO Agios Presents Data from Single Agent Dose-Escalation Arm of Phase 1 Study of AG-270, a MAT2A Inhibitor, in Patients with MTAP-Deleted Tumors

– Plasma SAM Biomarker Indicates Robust Target Engagement at Well Tolerated Doses; AG-270 Maximum Tolerated Dose Determined to be 200 mg Once Daily – – Combination Arms of Phase 1 Study Evaluating AG-270 in Combination with Taxanes in Non-Small Cell Lung Cancer an...

In case you are interested AGIO - Agios Presents Data from Single Agent Dose-Escalation Arm of Phase 1 Study of AG-270, a MAT2A Inhibitor, in Patients with MTAP-Deleted Tumors
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent AGIO News
More AGIO News